The corona vaccines of Astraznica, a British-Swedish pharmaceutical company, will soon be added to the stock of vaccines in Israel.
"Israel Today" has learned that at the end of September a small stock of the vaccine, called Waxabria, will arrive in Israel.
The vaccine is intended for use in a small group of people: those who have developed an allergic reaction after a first vaccine with a piper or vaccine engines for other reasons.
Dr. Sharon Elrai Price, Head of Public Health Services at the Ministry of Health, commented on the arrival of the vaccine at the hearing, saying:
It is an important solution for vaccine engines or for people who have developed a reaction following other vaccines. "
The Astrazenica vaccine is in a different technology from that of the Pfizer and Modern mRNA vaccines.
It is a vaccine based on adenovirus (another virus that causes respiratory disease), which is genetically engineered to contain some of the genetic material of the corona virus, and will cause a strong immune system reaction against it.
Although Israel originally purchased options for about 10 million doses of Astraznica vaccine, it later sought to change the agreement.
It is estimated that a few thousand will arrive in Israel in the first phase.
